TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20338746
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy followed by low intensity 'maintenance' chemotherapy (6-drug regimen with local therapy of surgery and/or radiotherapy followed by 9 courses of vincristine, actinomycin D and cyclophosphamide (VAC)) for SRG.
Study: 20338746
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose monotherapy followed by low dose maintenance chemotherapy (VAC) for PRG.
Study: 20339536
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day simvastatin for 6 weeks
Study: 20339536
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day pravastatin for 24 weeks
Study: 20339536
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day atorvastatin for 8 weeks
Study: 20346127
Drug: Latanoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost/timolol fixed combination (FC)
Study: 20350136
Drug: Intermediate CYP2D6
Normalized name: PREVOTELLA INTERMEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate CYP2D6 metabolism (0.5 SGD)
Study: 20350189
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment during pregnancy (IPTp)
Study: 20350192
Drug: Artemisinin derivatives
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin derivatives treatment
Study: 20354809
Drug: Chronic InterStim
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic InterStim Therapy device (Medtronic) implantation
Study: 20363090
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR-NTX) 380 mg, intramuscular, with monthly medical management (MM)
Study: 20363090
Drug: Monthly medical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly medical management (MM)
Study: 20364383
Drug: Intraepidermal injection
Normalized name: HYALURONIC ACID 2.5 g INTRAEPIDERMAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraepidermal injection of autologous dissociated epidermal cell suspension
Study: 20368313
Drug: Glomerular filtration
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glomerular filtration rate (GFR) reference values measured at inclusion and weekly for the first month using 12-hour urine specimens.
Study: 20368434
Drug: Decitabine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (20 mg/m² i.v. over 1 h on days 1 to 10)
Study: 20369375
Drug: Enzastaurin 500
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin 500 mg/day
Study: 20372873
Drug: Low-dose growth
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 24 weeks
Study: 20372873
Drug: Low-dose growth
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 48 weeks
Study: 20372873
Drug: Low-dose growth
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 24 and 48 weeks
Study: 20372873
Drug: Low-dose growth
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day)
Study: 20378407
Drug: Vorinostat 300
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 300 mg once daily
Study: 20378407
Drug: Vorinostat 400
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 400 mg once daily
Study: 20378407
Drug: Vorinostat (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (various doses)
Study: 20378616
Drug: Ganirelix (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganirelix (GnRH antagonist)
Study: 20378730
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) - 6 months of open-label, daily, self-administered INH.
Study: 20378730
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) - received by 480 participants.
Study: 20378730
Drug: Age greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age greater than 35 years and presence of hepatitis B virus core antibody.
Study: 20378927
Drug: Modified slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified slow-release oral testosterone
Study: 20378927
Drug: Immediate-release oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oral testosterone
Study: 20378927
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone with finasteride
Study: 20378927
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone without finasteride
Study: 20384395
Drug: Propiverine 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 5, 10 and 15 mg twice daily for 14 days
Study: 20385792
Drug: Lenalidomide-bortezomib-dexamethasone combination
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide-bortezomib-dexamethasone combination therapy
Study: 20385942
Drug: Weekly examinations
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly examinations for type 2 ROP
Study: 20386074
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) therapy (2 g/kg)
Study: 20386909
Drug: MK-0457 (24-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0457 (24-h continuous intravenous infusion at 64 mg/m(2)/h every 21 days)
Study: 20386909
Drug: MK-0457 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0457 (100 mg oral dose administered 48 h prior to CIV infusion)
Study: 20386909
Drug: MK-0457 (24-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0457 (24-h continuous intravenous infusion)
Study: 20390419
Drug: TSU-68 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSU-68 at a dose of 200 mg bid
Study: 20391423
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 400 mg/kg every 3 weeks from week 12 to week 24 of gestation
Study: 20393132
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of mitoxantrone for the second consolidation course for low- and intermediate-risk patients.
Study: 20394026
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion (CII) with oral intake
Study: 20398925
Drug: MDV3100 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDV3100 30 mg
Study: 20398925
Drug: MDV3100 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDV3100 60 mg
Study: 20398925
Drug: MDV3100 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDV3100 240 mg
Study: 20398925
Drug: MDV3100 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDV3100 (various doses)
Study: 20398925
Drug: MDV3100 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDV3100 (60 mg to 480 mg)
Study: 20398959
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 12 weeks, then maintenance therapy twice per week for 12 weeks if clear or almost clear (cohort B)
Study: 20398959
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 24 weeks (cohort A)
Study: 20398959
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 12 weeks, then returned to daily dosing after relapse during maintenance (cohort C)
Study: 20400682
Drug: WT1 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WT1 peptide vaccine (4 peptides, 200 microg each) with immune adjuvants, administered over 12 weeks (6 vaccinations)
Study: 20400682
Drug: WT1 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WT1 peptide vaccine
Study: 20400762
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) for 48 h
Study: 20403857
Drug: Drug-induced sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-induced sleep endoscopy with intravenous propofol infusion
Study: 20408846
Drug: ofatumumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ofatumumab (4 weekly infusions)
Study: 20410100
Drug: SNPs in
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNPs in tumor necrosis factor receptor superfamily member 10b (TNFRSF10B)
Study: 20412178
Drug: Rifaximin 600
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 600 mg/d for 14 days
Study: 20413029
Drug: Combined HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HF device diagnostics (positive criteria: long atrial fibrillation duration, rapid ventricular rate during atrial fibrillation, high fluid index, low patient activity, abnormal autonomics, notable device therapy, or very high fluid index)
Study: 20413733
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment with LDLR haplotype 5 (LDLR L5) in blacks
Study: 20413733
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment with combined LDLR L5 and HMGCR haplotypes in blacks
Study: 20413733
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment measuring LDL receptor surface expression
Study: 20418798
Drug: CD4 count
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD4 count criteria for initiating antiretroviral therapy
Study: 20420675
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to organic or inorganic allergenic or irritant compounds
Study: 20421452
Drug: Deferasirox (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (30 to 40 mg/kg per day)
Study: 20424554
Drug: IL-6 -572C/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 -572C/G polymorphism
Study: 20424554
Drug: IL-10 -1082A/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 -1082A/G polymorphism
Study: 20426845
Drug: Insulin like
Normalized name: IGF 1 - Insulin like growth factor 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin like growth factor-I (IGF-I) in patients with aSAH, mean IGF-I concentrations for days one to five were 8.1 +/- 3.5 nmol/l.
Study: 20426845
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (elective aneurysm surgery), mean IGF-I concentrations for days one to five were 11.2 +/- 3.1 nmol/l.
Study: 20427509
Drug: l-T(4) replacement
Normalized name: L-3972-T
DrugBank: L-3972-T (DB17441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-T(4) replacement therapy
Study: 20427701
Drug: Oral forodesine
Normalized name: Forodesine
DrugBank: Forodesine (DB06185)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral forodesine (200 mg/d) for up to 24 weeks
Study: 20429726
Drug: Lipiodol injection
Normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol injection during flexible cystoscopy into the submucosa of the bladder wall
Study: 20429726
Drug: Lipiodol injection
Normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol injection
Study: 20429821
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol 100/50 microg combination (FSC)
Study: 20429821
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (FSC and FP)
Study: 20430469
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg daily
Study: 20432813
Drug: One-year lifestyle
Normalized name: segesterone
DrugBank: Segesterone (DB14584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-year lifestyle intervention program (physical activity, nutrition course, behavioral therapy)
Study: 20433539
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hypertension (specifics not provided)
Study: 20433746
Drug: New electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New electronic device for self-injection of subcutaneous interferon beta-1a, 44 mcg three times weekly, for 12 weeks.
Study: 20433746
Drug: New electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New electronic device for self-injection of subcutaneous interferon beta-1a.
Study: 20435233
Drug: Caspofungin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (70 mg for one dose, followed by 50 mg daily)
Study: 20435233
Drug: Micafungin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (100 mg daily)
Study: 20435244
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 3.75-mg depot, administered as 6 monthly intramuscular injections.
Study: 20435244
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 3.75-mg depot
Study: 20439622
Drug: Eliglustat tartrate
Normalized name: eliglustat tartrate
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eliglustat tartrate (Genz-112638) administered twice daily at 50- or 100-mg doses based on plasma drug concentrations.
Study: 20442365
Drug: Cytarabine-based induction
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine-based induction therapy followed by 1 consolidation
Study: 20444959
Drug: Breakfast (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast (500 kcal, 21 g protein)
Study: 20446946
Drug: Aspirin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (single antiplatelet therapy)
Study: 20447528
Drug: MR-proANP (≥120
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-proANP (≥120 pmol/l)
Study: 20453640
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Abciximab administered in 1086 patients)
Study: 20456292
Drug: Injecting drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injecting drugs
Study: 20456292
Drug: Using illegal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using illegal drugs before or during sex
Study: 20458050
Drug: Cediranib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib (45 mg/d)
Study: 20460644
Drug: Flavopiridol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavopiridol (40 mg/m2 IV bolus + 60 mg/m2 continuous IV infusion)
Study: 20461780
Drug: Rituximab 1000
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 1000 mg intravenously at baseline and week 2
Study: 20462451
Drug: Fertility treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fertility treatments
Study: 20463041
Drug: Habitual dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habitual dietary ALA intake (1-g increment)
Study: 20463041
Drug: Twin with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twin with 1-g higher ALA intake compared to co-twin
Study: 20465593
Drug: Wireless motility
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless motility capsule (WMC) and Radiopaque markers (ROM)
Study: 20466783
Drug: Insulin suppression
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin suppression of lipolysis
Study: 20466853
Drug: Dasatinib 50
Normalized name: dasatinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 50 mg by mouth twice per day (or 100 mg daily) for the first 14 days of each of 8 cycles of hyper-CVAD, followed by maintenance daily dasatinib and monthly vincristine and prednisone for 2 years.
Study: 20466853
Drug: Dasatinib with
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib with chemotherapy
Study: 20471725
Drug: Butyrate enemas
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrate enemas (100mM sodium butyrate, 60 ml daily for 20 days)
Study: 20472746
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib 0.3 mg administered every 6 weeks for 48 weeks
Study: 20478057
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclophosphamide (300 mg/m2) followed by GM-CSF + GV1001 vaccinations
Study: 20484311
Drug: Asymmetric dimethylarginine
Normalized name: dimethylamine
DrugBank: N,N-dimethylarginine (DB01686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymmetric dimethylarginine (ADMA) levels in the highest quartile (> 0.84 mumol/l)
Study: 20484443
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (200 IU daily for 1 year)
Study: 20484456
Drug: Low intake
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intake of n-3 LCPUFAs (< approximately 0.30 g/d)
Study: 20489620
Drug: Imatinib (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (dose escalation)
Study: 20489620
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of imatinib dose to achieve a target imatinib plasma level
Study: 21140148
Drug: Standard imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard imatinib dosing
Study: 20491740
Drug: 1200 IU
Normalized name: Vitamin E 1200 IU Oral Capsule, Liquid Filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 IU vitamin D3 once daily for 12 months
Study: 20491780
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (1.3 mg/m²)
Study: 20491780
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (1.8 mg/m²)
Study: 20491780
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (both doses)
Study: 20508619
Drug: Cyclophosphamide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 400 mg/m(2)
Study: 20508619
Drug: Cyclophosphamide 500
Normalized name: cyclophosphamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 500 mg/m(2)
Study: 20511445
Drug: Lp(a) <10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) <10 mg/L and Hb A(1c) <5%
Study: 20511662
Drug: Intermediate risk
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate risk group (with at least one of: unmutated IGHV genes and/or IGHV3-21 usage, 11q deletion, β-2 microglobulin greater than 4 mg/L)
Study: 20516271
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg once-daily lamivudine (3TC) for children below 17 kg
Study: 20516271
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg once-daily lamivudine (3TC) for children over 17 kg
Study: 20516271
Drug: Didanosine-lamivudine-efavirenz treatment
Normalized name: efavirenz / lamivudine / tenofovir disoproxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine-lamivudine-efavirenz treatment
Study: 20518811
Drug: Pramlintide added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide added to mealtime insulin
Study: 20519658
Drug: Antibody positive
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody positive subjects (GAD-65 and IA-2 autoantibodies)
Study: 20519658
Drug: Antibody negative
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody negative subjects
Study: 20522711
Drug: Fibril-reactive, amyloidolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibril-reactive, amyloidolytic murine IgG1 mAb 11-1F4 labeled with I-124, infused with less than 1 mg (∼ 74 MBq) of GMP-grade antibody.